Liposomal bupivacaine versus bupivacaine hydrochloride: are we changing the outcomes?

Alaa Abd-Elseyed

ABSTRACT

Hanns-Christian *et al*¹ conducted a literature review with the objective of determining whether there is a difference in postoperative pain scores and opioid consumption between patients who received liposomal bupivacaine and patients who received bupivacaine hydrochloride.

The authors concluded that the beneficial effect on both postoperative pain scores and opioid consumption was small but not clinically relevant.¹

Correspondence to Dr Alaa Abd-Elseyed, University of Wisconsin Madison School of Medicine and Public Health, Madison, WI 53705, USA; alaaawny@hotmail.com

Contributors AA-E designed and produced the infographic.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© American Society of Regional Anesthesia & Pain Medicine 2021. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Abd-Elseyed A. *Reg Anesth Pain Med* 2021;46:499.

Received 25 March 2021

Revised 27 March 2021

Accepted 30 March 2021

Published Online First 9 April 2021

► <http://dx.doi.org/10.1136/rapm-2020-102427>

Reg Anesth Pain Med 2021;46:499.

doi:10.1136/rapm-2021-102683

REFERENCE

- Dinges H-C, Wiesmann T, Otremba B, Hanns-Christian D, *et al*. The analgesic efficacy of liposomal bupivacaine compared with bupivacaine hydrochloride for the prevention of postoperative pain: a systematic review and meta-analysis with trial sequential analysis. *Reg Anesth Pain Med* 2021;46:490–8.